Clinical trials: Childhood Neoplasm
Brain Tumor, Central Nervous System Tumor
Combination Chemotherapy Followed by Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Medulloblastoma or CNS Germ Cell Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so that they stop growing or die. bone marrow transplantation and peripheral stem cell transplantation may allow the doctor to give higher…
- Trial name
- NCT00002594
- Testing
- Sargramostim, cyclophosphamide, melphalan
- Where
- 118 sites in United States, Australia and 4 more
- Volunteers
- 31 people
- Sponsor
- Children's Oncology Group
Acral Lentiginous Melanoma, Central Nervous System Melanoma
Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease
This phase I/Ib trial studies the side effects and best dose of intrathecal nivolumab, and how well it works in combination with intravenous nivolumab in treating patients with leptomeningeal disease.
- Conditions
- Acral Lentiginous Melanoma, Central Nervous System Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Leptomeningeal Neoplasm
- Trial name
- NCT03025256
- Testing
- Biospecimen Collection, Computed Tomography, Lumbar Puncture
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- M.D. Anderson Cancer Center
Neoplasm Malignant
Pharmacokinetics and Safety Study of Cabazitaxel in Cancer Patients With Renal Impairment
Primary Objective: To assess potential impact of moderate and severe renal impairment on the pharmacokinetics of cabazitaxel Secondary Objective: To assess the safety of cabazitaxel in patients with various degrees of renal…
- Trial name
- NCT01527929
- Testing
- Cabazitaxel XRP6258
- Where
- 7 sites in Belgium, Italy and 3 more
- Volunteers
- 25 people
- Sponsor
- Sanofi
Anal Squamous Cell Carcinoma, Colorectal Neoplasms
Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers
REFIT-MSS is a non-randomized, multicenter, open-label, multi-cohort, 2-stage, phase II trial to evaluate the efficacy and safety of regorafenib in combination with tislelizumab (referred as Rego-Tisle) in adult patients with…
- Conditions
- Anal Squamous Cell Carcinoma, Colorectal Neoplasms, Soft Tissue Sarcoma, Malignant Pleural Mesothelioma
- Trial name
- REFIT-MSS (NCT05582031)
- Testing
- Regorafenib in combination with Tislelizumab
- Sponsor
- Translational Research in Oncology
Advanced Solid Tumor, Metastatic Solid Tumor
A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors
This study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of WM-S1-030 in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Colorectal Cancer, Lung Cancer
- Trial name
- NCT04801095
- Testing
- WM-S1-030
- Where
- 6 sites in Australia, South Korea
- Volunteers
- 100 people
- Sponsor
- Wellmarker Bio
Cancer
A Videogame Intervention for Children With Cancer
The investigators aim to improve the quality of life and well-being of children with cancer in low- and middle-income countries through a videogame intervention.
- Trial name
- NCT05796895
- Testing
- Videogame, WhatsApp
- Volunteers
- 70 people
- Sponsor
- Aga Khan University
Recurrent Childhood Acute Lymphoblastic Leukemia
Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
This Phase II trial is studying how well giving epratuzumab together with an established chemotherapy platform works in treating young patients with relapsed acute lymphoblastic leukemia.
- Trial name
- NCT00098839
- Testing
- L-asparaginase, doxorubicin hydrochloride, therapeutic hydrocortisone
- Where
- 46 sites in United States, Australia and 2 more
- Volunteers
- 134 people
- Sponsor
- Children's Oncology Group
Neuroblastoma, Medulloblastoma
Molecular-Guided Therapy for Relapsed and Refractory Childhood Cancer
The purpose of this study is to test the feasibility (ability to be done) of experimental technologies to determine a tumor's molecular makeup (gene expression profile) and mutations.
- Conditions
- Neuroblastoma, Medulloblastoma, Brain Tumors, Rare Tumors
- Trial name
- NCT01802567
- Testing
- Guided Therapy- Pediatric Gene Analysis Platform
- Where
- 13 sites in United States
- Volunteers
- 52 people
- Sponsor
- Giselle Sholler
Non-small Cell Lung Cancer
A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen
This study will compare PF-00299804 given orally on continuous schedule to the approved drug, erlotinib, in patients whose non-small cell lung cancer has progressed after chemotherapy; patients will be randomized to receive one…
- Trial name
- NCT00769067
- Testing
- Erlotinib, PF-00299804
- Where
- 59 sites in United States, Australia and 10 more
- Volunteers
- 188 people
- Sponsor
- Pfizer
Cancer Screening Tests
Helping Patients and Providers Make Better Decisions About Colorectal Cancer Screening
Precision prevention holds great promise for colorectal cancer (CRC) screening but has not been adequately explored. A patient's chance of having an advanced colorectal neoplasm (ACN), i.e.
- Trial name
- NCT04683731
- Testing
- Decision aid without personalized message, Decision aid with personalized message, Provider notification without personalized message
- Where
- 2 sites in United States
- Volunteers
- 1,111 people
- Sponsor
- Indiana University
Carcinoma, Renal Cell
Exploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography as a Predictive Marker for Therapy With RAD001 in Metastatic Renal Cell Cancer
The purpose of this study is to learn if PET scanning can predict the degree of tumor shrinkage with the study drug RAD001 in subjects who have advanced renal cancer.
- Trial name
- NCT00529802
- Testing
- RAD001
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of Chicago
Breast Neoplasm, Colorectal Neoplasm
Decision Aid Website in Helping to Make Decisions About Fertility in Participants With Cancer
This trial studies how well a decision aid website works in helping to make decisions about fertility in participants with cancer.
- Conditions
- Breast Neoplasm, Colorectal Neoplasm, Female Reproductive System Neoplasm, Health Care Provider
- Trial name
- NCT03141437
- Testing
- Best Practice, Educational Intervention, Internet-Based Intervention
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- M.D. Anderson Cancer Center
Childhood Cancer, Child Malnutrition
Body Composition and Nutritional Status in Pediatric Patients With Hematological Malignancies
Introduction: Annually 400,000 children are diagnosed with cancer in the world. Approximately 90% live in low/middle-income countries, with survival rates of 10-30%.
- Conditions
- Childhood Cancer, Child Malnutrition, Childhood Obesity
- Trial name
- HM (NCT04764695)
- Testing
- D2O dilution technique
- Where
- Mexico
- Volunteers
- 38 people
- Sponsor
- Universidad de Sonora
Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer
NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial
This is a multicenter screening protocol designed to identify patients with NSCLC who have tumor mutations in the KEAP1 or NRF2/NFE2L2 genes in order to determine potential eligibility for a biomarker selected clinical trial…
- Conditions
- Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung, KEAP1 Gene Mutation
- Trial name
- NCT04698681
- Where
- 63 sites in United States
- Volunteers
- 20 people
- Sponsor
- Calithera Biosciences, Inc
Extensive Disease Small Cell Lung Cancer
Sintilimab Combined With Anlotinib as Second or Further-line Therapy for ED-SCLC
Small cell lung cancer (SCLC) accounts for 10-15% of lung cancer. More than 70% of SCLC patients are diagnosed with advanced stage (ED-SCLC) at diagnosis.
- Trial name
- NCT04055792
- Testing
- Sintilimab
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Henan Cancer Hospital
Neoplasm
A Phase I Study of Systemic Gene Therapy With SGT-94 in Patients With Solid Tumors
This is a Phase I study designed to evaluate the safety and maximum tolerated dose (MTD) of SGT-94, a novel, tumor-targeted, systemic gene therapy agent for cancer.
- Trial name
- SGT94-01 (NCT01517464)
- Testing
- SGT-94
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- SynerGene Therapeutics, Inc.
Colorectal Cancer, Metastatic Cancer
Surgery With or Without Radiofrequency Ablation Followed by Irinotecan in Treating Patients With Colorectal Cancer That is Metastatic to the Liver
RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. Combining radiofrequency ablation with surgery may kill more tumor cells.
- Trial name
- NCT00030563
- Testing
- irinotecan hydrochloride, adjuvant therapy, conventional surgery
- Where
- 3 sites in United States, Canada
- Sponsor
- University of Washington
Minimal Residual Disease, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes
Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant
This phase I/II trial studies the side effects and best dose of donor lymphocyte infusions when given together with daratumumab and to see how well they work in treating participants with acute myeloid leukemia that has come back…
- Conditions
- Minimal Residual Disease, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia
- Trial name
- NCT03537599
- Testing
- Daratumumab, Donor Lymphocyte Infusion, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Sumithira Vasu
Childhood Cancer, Multiple Diseases
Prospective Trial of Vaccine Responses in Childhood Cancer Survivors
This study will look at your body's response to the new immunizations. We want to see how well they will protect you. Immunization is the same as vaccination. Our goal is to protect you as much as we can.
- Trial name
- NCT00505063
- Testing
- Immunization Schedule patients <7 years., Immunization Schedule patients > or = to 7 years and <11 years of age, Immunization Schedule patients > or = to 11 years of age
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer, Brachytherapy
PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer
PRO-BOOST-N is a prospective, multicenter, randomized phase II/III clinical trial for patients with prostate cancer and pelvic lymph node involvement (cN1M0) confirmed by PSMA PET/CT, without distant metastatic disease.
- Conditions
- Prostate Cancer, Brachytherapy, Stereotactic Body Radiation Therapy (SBRT), Dose Escalation: Solid Tumors
- Trial name
- PRO-BOOST-N (NCT07426094)
- Testing
- Ultrahypofractionated Whole-Pelvis Radiotherapy, SBRT-Based Prostate Radiotherapy (No Boost), Ablative Prostate Boost
- Where
- Poland
- Volunteers
- 600 people
- Sponsor
- Affidea Nu-med Center of Oncological DIagnostics and Therapy
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.